Free Trial

Curaleaf (OTCMKTS:CURLF) Stock Price Down 11.5% - What's Next?

Curaleaf logo with Medical background

Key Points

  • Curaleaf Holdings, Inc. shares fell by 11.5% to $1.70, with trading volume declining by 41% compared to its average session.
  • The company reported a quarterly EPS of ($0.07), aligning with analysts' expectations, while facing a negative net margin and return on equity.
  • Curaleaf operates in the cannabis industry, offering a range of products including flower, concentrates, and edibles.
  • Want stock alerts on Curaleaf? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report) shares traded down 11.5% during trading on Wednesday . The company traded as low as $1.66 and last traded at $1.70. 382,399 shares were traded during trading, a decline of 41% from the average session volume of 647,366 shares. The stock had previously closed at $1.92.

Curaleaf Price Performance

The stock's 50-day moving average is $1.01 and its 200 day moving average is $1.05. The stock has a market capitalization of $1.16 billion, a PE ratio of -5.58 and a beta of 0.69. The company has a quick ratio of 0.70, a current ratio of 1.41 and a debt-to-equity ratio of 1.08.

Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.07) EPS for the quarter, meeting analysts' consensus estimates of ($0.07). Curaleaf had a negative net margin of 17.37% and a negative return on equity of 14.12%. As a group, equities analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current year.

About Curaleaf

(Get Free Report)

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Curaleaf Right Now?

Before you consider Curaleaf, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.

While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines